• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Crude Oil Falls Sharply; Apollomics Shares Plunge

    10/23/23 2:39:29 PM ET
    $AKU
    $APLM
    $INVO
    $LICY
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKU alert in real time by email

    U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining over 100 points on Monday.

    The Dow traded down 0.19% to 33,062.85 while the NASDAQ rose 0.80% to 13,088.09. The S&P 500 also rose, gaining, 0.28% to 4,236.12.

    Check This Out: This Analyst With 85% Accuracy Rate Sees More Than 42% Upside In Amazon.com - Here Are 5 Stock Picks For Last Week From Wall Street's Most Accurate Analysts

     

    Leading and Lagging Sectors

     

    Communication services shares rose by 1.3% on Monday.

    In trading on Monday, energy shares dipped by 1.9%.

     

    Top Headline

     

    The Chicago Fed National Activity Index climbed to +0.02 in September versus a revised reading of -0.22 in the prior month.

     

    Equities Trading UP

     

    LumiraDx Limited (NASDAQ:LMDX) shares shot up 282% to $0.3321 after the company reported a strategic collaboration with AstraZeneca and Everton in the Community to set up England’s first community-based heart and lung screening hub.

    Shares of INVO Bioscience, Inc. (NASDAQ:INVO) got a boost, shooting 295% to $2.1350 as the company agreed to acquire NAYA Biosciences in an all-stock transaction.

    Akumin Inc. (NASDAQ:AKU) shares were also up, gaining 149% to $0.3629 after the company reached an agreement with Stonepeak to become a private company.

     

    Equities Trading DOWN

     

    Li-Cycle Holdings Corp. (NYSE:LICY) shares dropped 44% to $1.28 after the company announced plans to halt construction work on its Rochester Hub project, pending completion of a comprehensive review of the go-forward strategy for the project..

    Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) were down 39% to $17.20 after the company announced it presented clinical activity and safety data from its Phase 1/1b trial of RMC-6236.

    Apollomics, Inc. (NASDAQ:APLM) was down, falling 43% to $1.00 after the company announced the presentation of vebreltinib efficacy and safety data from the KUNPENG clinical trial at ESMO 2023.

    Also Check This Out: Top 4 Consumer Stocks That May Crash This Quarter

     

    Commodities

     

    In commodity news, oil traded down 2.6% to $85.79 while gold traded down 0.3% at $1,987.60.

    Silver traded down 1.4% to $23.185 on Monday while copper rose 0.6% to $3.5840.

     

    Euro zone

     

    European shares closed mixed today. The eurozone’s STOXX 600 fell 0.13%, London’s FTSE 100 fell 0.37% while Spain’s IBEX 35 Index fell 0.37% The German DAX rose 0.02% French CAC 40 rose 0.50%, while Italy’s FTSE MIB Index gained 0.74%.

     

    Asia Pacific Markets

     

    Asian markets closed lower on Monday, with Japan’s Nikkei 225 falling 0.83% and China’s Shanghai Composite Index falling 1.47%. India’s S&P BSE Sensex, meanwhile, fell 0.8%.

    Food prices in Singapore rose by 4.3% year-over-year in September following a 4.8% increase in August. Singapore's annual inflation rate rose to 4.1% in September from August's level of 4.0%.

     

    Economics

     

    The Chicago Fed National Activity Index climbed to +0.02 in September versus a revised reading of -0.22 in the prior month.

    Now Read This: $15M Bet On Day One Biopharmaceuticals? Check Out These 3 Stocks Insiders Are Buying

    Get the next $AKU alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKU
    $APLM
    $INVO
    $LICY

    CompanyDatePrice TargetRatingAnalyst
    Revolution Medicines Inc.
    $RVMD
    3/16/2026Buy
    Jefferies
    Revolution Medicines Inc.
    $RVMD
    2/27/2026$145.00Buy
    UBS
    Revolution Medicines Inc.
    $RVMD
    11/18/2025$75.00Outperform
    Wolfe Research
    Revolution Medicines Inc.
    $RVMD
    11/3/2025$77.00Outperform
    RBC Capital Mkts
    Revolution Medicines Inc.
    $RVMD
    10/21/2025$90.00Outperform
    Mizuho
    Revolution Medicines Inc.
    $RVMD
    10/16/2025$85.00Buy
    Stifel
    Revolution Medicines Inc.
    $RVMD
    9/12/2025$72.00Strong Buy
    Raymond James
    Revolution Medicines Inc.
    $RVMD
    9/5/2025$99.00Buy
    Truist
    More analyst ratings

    $AKU
    $APLM
    $INVO
    $LICY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress

    On track for readout of RASolute 302, a Phase 3 trial of daraxonrasib in second line metastatic PDAC, in first half of 2026Continues to advance broad late-stage pipeline, with five ongoing Phase 3 trials and three additional Phase 3 trials planned to initiate in 2026Expects to substantially complete enrollment in RASolve 301, a Phase 3 trial of daraxonrasib in previously treated NSCLC, this yearInitiated RASolute 305, the first Phase 3 trial for zoldonrasib, in first line metastatic PDAC harboring a RAS G12D mutationRevolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-s

    2/25/26 4:02:00 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference

    REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will participate in a fireside chat as part of the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3 at 9:50 a.m. ET. To listen to a live webcast of this event, or access an archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the company's website for at least 14 days. About Revoluti

    2/24/26 4:05:00 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026

    REDWOOD CITY, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2025 on Wednesday, February 25, 2026, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and full year, and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-prese

    2/18/26 4:05:00 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AKU
    $APLM
    $INVO
    $LICY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Wei Lin

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    3/19/26 6:57:49 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Kelsey Stephen Michael

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    3/19/26 6:57:08 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Goldsmith Mark A

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    3/19/26 6:56:39 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AKU
    $APLM
    $INVO
    $LICY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Revolution Medicines

    Jefferies resumed coverage of Revolution Medicines with a rating of Buy

    3/16/26 9:35:47 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UBS resumed coverage on Revolution Medicines with a new price target

    UBS resumed coverage of Revolution Medicines with a rating of Buy and set a new price target of $145.00

    2/27/26 8:31:41 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wolfe Research initiated coverage on Revolution Medicines with a new price target

    Wolfe Research initiated coverage of Revolution Medicines with a rating of Outperform and set a new price target of $75.00

    11/18/25 8:26:23 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AKU
    $APLM
    $INVO
    $LICY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Schroeder Thilo bought $59,999,962 worth of shares (1,304,347 units at $46.00) (SEC Form 4)

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    12/9/24 4:15:16 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Wellings Mark bought $9,031 worth of shares (6,250 units at $1.45), increasing direct ownership by 6% to 110,908 units (SEC Form 4)

    4 - Li-Cycle Holdings Corp. (0001828811) (Issuer)

    9/17/24 4:05:04 PM ET
    $LICY
    Environmental Services
    Industrials

    $AKU
    $APLM
    $INVO
    $LICY
    SEC Filings

    View All

    SEC Form 144 filed by Revolution Medicines Inc.

    144 - Revolution Medicines, Inc. (0001628171) (Subject)

    3/13/26 7:38:27 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Revolution Medicines Inc.

    144 - Revolution Medicines, Inc. (0001628171) (Subject)

    3/13/26 7:36:20 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Revolution Medicines Inc.

    144 - Revolution Medicines, Inc. (0001628171) (Subject)

    3/13/26 7:34:08 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AKU
    $APLM
    $INVO
    $LICY
    Financials

    Live finance-specific insights

    View All

    Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress

    On track for readout of RASolute 302, a Phase 3 trial of daraxonrasib in second line metastatic PDAC, in first half of 2026Continues to advance broad late-stage pipeline, with five ongoing Phase 3 trials and three additional Phase 3 trials planned to initiate in 2026Expects to substantially complete enrollment in RASolve 301, a Phase 3 trial of daraxonrasib in previously treated NSCLC, this yearInitiated RASolute 305, the first Phase 3 trial for zoldonrasib, in first line metastatic PDAC harboring a RAS G12D mutationRevolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-s

    2/25/26 4:02:00 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026

    REDWOOD CITY, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2025 on Wednesday, February 25, 2026, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and full year, and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-prese

    2/18/26 4:05:00 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

    Company is winding down global enrollment for the RASolute 302 clinical trial studying daraxonrasib in patients with previously treated PDAC and remains on track for data readout in 2026Company has initiated RASolute 304, a Phase 3 clinical trial of daraxonrasib as adjuvant treatment for patients with resectable PDAC, and remains on track to initiate RASolute 303 for patients with first line metastatic PDAC this yearDaraxonrasib has received FDA Breakthrough Therapy Designation, Orphan Drug Designation and a Commissioner's National Priority VoucherNew leadership appointments strengthened global development and commercialization capabilitiesRevolution Medicines to hold webcast today at 4:30 p

    11/5/25 4:02:00 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AKU
    $APLM
    $INVO
    $LICY
    Leadership Updates

    Live Leadership Updates

    View All

    Apollomics, Inc. Company Operational Continuity Update

    FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), today announced the following company operational update. Apollomics is a clinical-stage biotechnology company advancing innovative oncology therapies to transform the treatment landscape for patients with few or no options. With a pipeline of nine product candidates across 11 programs, including six in clinical development, the Company is focused on tackling some of the most challenging cancers, such as lung cancer, brain cancer, and other solid tumors. Apollomics' strategic approach combines targeted therapies, immuno-oncology, and novel mechanisms of action designed to

    10/13/25 9:22:37 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer

    REDWOOD CITY, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the appointment of Alan Sandler, M.D. into the newly created role of chief development officer, as well as the appointment of regional general managers in the U.S. and Europe. "I am delighted to welcome Alan as our chief development officer as we pursue our bold vision to develop new global standards of care for patients with RAS-addicted cancers," said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. "As a physician-

    9/29/25 9:00:15 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Nano One Announces Resignation of Paul Matysek and Appointment of Industry Veteran Anthony Tse as New Chair of the Board of Directors

    VANCOUVER, BC / ACCESSWIRE / October 1, 2024 / (TSX:NANO)(OTC:NNOMF)(Frankfurt:LBMB)Nano One® Materials Corp. ("Nano One" or the "Company"), a clean technology company with a patented process for the low-cost, low-GHG production of lithium-ion battery cathode active materials (CAM), is pleased to announce that Mr. Anthony Tse has been appointed Chair of the Board of Directors.Mr. Tse will succeed Paul Matysek, who is the founding Chair of Nano One and resigning as part of a planned transition to an advisory role that supports the incoming Chair and Board. Mr. Matysek is honoured to have presided over Nano One's growth and leadership for more than a decade."On behalf of Nano One and our share

    10/1/24 3:05:00 AM ET
    $BEN
    $LICY
    Investment Managers
    Finance
    Environmental Services
    Industrials

    $AKU
    $APLM
    $INVO
    $LICY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Li-Cycle Holdings Corp.

    SC 13D/A - Li-Cycle Holdings Corp. (0001828811) (Subject)

    12/9/24 6:03:27 PM ET
    $LICY
    Environmental Services
    Industrials

    Amendment: SEC Form SC 13G/A filed by Revolution Medicines Inc.

    SC 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)

    11/8/24 10:52:39 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Li-Cycle Holdings Corp.

    SC 13D/A - Li-Cycle Holdings Corp. (0001828811) (Subject)

    10/15/24 4:30:29 PM ET
    $LICY
    Environmental Services
    Industrials